Table of Content

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. INNOVATIVE APIS HOLDS THE LARGEST MARKET SHARE IN TERMS OF ACTIVE PHARMACEUTICAL INGREDIENTS TYPE
3.2.2. MERCHANT APIS ARE THE FASTEST GROWING MANUFACTURERS
3.2.3. BIOTECH IS THE FASTEST GROWING SYNTHESIS SEGMENT
3.2.4. ONCOLOGY IS THE MAJORLY USED APPLICATION

4. MARKET DYNAMICS
4.1. MARKET SCOPE & DEFINITION
4.2. MARKET DRIVERS
4.2.1. GROWING GERIATRIC POPULATION
4.2.2. GROWING PREVALENCE OF INFECTIOUS DISEASES AND HOSPITAL ACQUIRED INFECTIONS
4.2.3. INCREASING INCIDENCE OF AGE-RELATED DISEASES
4.3. MARKET RESTRAINTS
4.3.1. HIGH COST OF INVESTMENT AND PRODUCTION COST
4.3.2. AGGRESSIVE COMPETITION AMONG API MANUFACTURERS
4.4. MARKET OPPORTUNITIES
4.4.1. GAINING POPULARITY FOR TARGETED THERAPY
4.4.2. GROWING PREFERENCE FOR OUTSOURCING APIS
4.4.3. IMPLEMENTING MEASURES AGAINST COUNTERFEIT DRUGS
4.5. MARKET CHALLENGES
4.5.1. STRINGENT GOVERNMENT REGULATIONS
4.5.2. AVAILABILITY OF COUNTERFEIT PRODUCTS

5. MARKET BY TYPES
5.1. GENERIC APIS
5.2. INNOVATIVE APIS

6. MARKET BY MANUFACTURERS
6.1. CAPTIVE APIS
6.2. MERCHANT APIS

7. MARKET BY SYNTHESIS
7.1. BIOTECH
7.1.1. MONOCLONAL ANTIBODIES
7.1.2. RECOMBINANT PROTEINS
7.1.3. VACCINES
7.2. SYNTHETIC

8. MARKET BY APPLICATION
8.1. CARDIOVASCULAR DISEASE
8.2. ONCOLOGY
8.3. CNS AND NEUROLOGICAL DISORDERS
8.4. ORTHOPEDIC DISORDERS
8.5. ENDOCRINOLOGY
8.6. PULMONOLOGY
8.7. GASTROINTESTINAL DISORDERS
8.8. NEPHROLOGY
8.9. OPHTHALMOLOGY
8.10. OTHER APPLICATION

9. KEY ANALYTICS
9.1. PORTER’S FIVE FORCES MODEL
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE
9.1.3. BARGAINING POWER OF BUYERS
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. THREAT OF COMPETITIVE RIVALRY
9.2. PESTEL ANALYSIS
9.3. SUPPLY CHAIN ANALYSIS
9.4. OPPORTUNITY MATRIX

10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. THE UNITED STATES
10.1.2. CANADA

11. COMPETITIVE LANDSCAPE
11.1. MARKET POSITION ANALYSIS
11.2. COMPANY PROFILES
11.2.1. ABBVIE, INC.
11.2.2. ALBEMARLE CORPORATION
11.2.3. AUROBINDO PHARMA
11.2.4. BAYER AG
11.2.5. BOEHRINGER INGELHEIM GMBH
11.2.6. BRISTOL-MYERS SQUIBB
11.2.7. CIPLA
11.2.8. DR. REDDY’S LABORATORIES
11.2.9. ELI LILLY AND COMPANY
11.2.10. LONZA GROUP AG
11.2.11. MERCK & CO., INC.
11.2.12. MYLAN N.V.
11.2.13. NOVARTIS
11.2.14. SUN PHARMACEUTICALS INDUSTRIES, LTD.
11.2.15. TEVA PHARMACEUTICAL INDUSTRIES LTD.


TABLES LIST
TABLE 1 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
TABLE 2 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 3 NORTH AMERICA GENERIC APIS MARKET 2019-2027 ($ MILLION)
TABLE 4 NORTH AMERICA INNOVATIVE APIS MARKET 2019-2027 ($ MILLION)
TABLE 5 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURERS 2019-2027 ($ MILLION)
TABLE 6 NORTH AMERICA CAPTIVE APIS MARKET 2019-2027 ($ MILLION)
TABLE 7 NORTH AMERICA MERCHANT APIS MARKET 2019-2027 ($ MILLION)
TABLE 8 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHESIS 2019-2027 ($ MILLION)
TABLE 9 NORTH AMERICA BIOTECH MARKET 2019-2027 ($ MILLION)
TABLE 10 NORTH AMERICA BIOTECH MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 11 NORTH AMERICA MONOCLONAL ANTIBODIES MARKET 2019-2027 ($ MILLION)
TABLE 12 NORTH AMERICA RECOMBINANT PROTEINS MARKET 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA VACCINES MARKET 2019-2027 ($ MILLION)
TABLE 14 NORTH AMERICA SYNTHETIC MARKET 2019-2027 ($ MILLION)
TABLE 15 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 16 NORTH AMERICA CARDIOVASCULAR DISEASE MARKET 2019-2027 ($ MILLION)
TABLE 17 NORTH AMERICA ONCOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 18 NORTH AMERICA CNS AND NEUROLOGICAL DISORDERS MARKET 2019-2027 ($ MILLION)
TABLE 19 NORTH AMERICA ORTHOPEDIC DISORDERS MARKET 2019-2027 ($ MILLION)
TABLE 20 NORTH AMERICA ENDOCRINOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 21 NORTH AMERICA PULMONOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 22 NORTH AMERICA GASTROINTESTINAL DISORDERS MARKET 2019-2027 ($ MILLION)
TABLE 23 NORTH AMERICA NEPHROLOGY MARKET 2019-2027 ($ MILLION)
TABLE 24 NORTH AMERICA OPHTHALMOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 25 NORTH AMERICA OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
TABLE 26 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 27 ACTIVE PHARMACEUTICAL INGREDIENTS COMPANY MARKET POSITION ANALYSIS 2017

FIGURES LIST
FIGURE 1 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 2 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY TYPES 2018 & 2027 (%)
FIGURE 3 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GENERIC APIS 2019-2027 ($ MILLION)
FIGURE 4 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY INNOVATIVE APIS 2019-2027 ($ MILLION)
FIGURE 5 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY MANUFACTURERS 2018 & 2027 (%)
FIGURE 6 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CAPTIVE APIS 2019-2027 ($ MILLION)
FIGURE 7 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MERCHANT APIS 2019-2027 ($ MILLION)
FIGURE 8 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY SYNTHESIS 2017 & 2027 (%)
FIGURE 9 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BIOTECH 2019-2027 ($ MILLION)
FIGURE 10 NORTH AMERICA BIOTECH MARKET BY MONOCLONAL ANTIBODIES 2019-2027 ($ MILLION)
FIGURE 11 NORTH AMERICA BIOTECH MARKET BY RECOMBINANT PROTEINS 2019-2027 ($ MILLION)
FIGURE 12 NORTH AMERICA BIOTECH MARKET BY VACCINES 2019-2027 ($ MILLION)
FIGURE 13 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHETIC 2019-2027 ($ MILLION)
FIGURE 14 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
FIGURE 15 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CARDIOVASCULAR DISEASE 2019-2027 ($ MILLION)
FIGURE 16 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ONCOLOGY 2019-2027 ($ MILLION)
FIGURE 17 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CNS AND NEUROLOGICAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 18 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ORTHOPEDIC DISORDERS 2019-2027 ($ MILLION)
FIGURE 19 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ENDOCRINOLOGY 2019-2027 ($ MILLION)
FIGURE 20 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY PULMONOLOGY 2019-2027 ($ MILLION)
FIGURE 21 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GASTROINTESTINAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 22 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY NEPHROLOGY 2019-2027 ($ MILLION)
FIGURE 23 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OPHTHALMOLOGY 2019-2027 ($ MILLION)
FIGURE 24 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OTHER APPLICATION 2019-2027 ($ MILLION)
FIGURE 25 PORTER’S FIVE FORCE MODEL
FIGURE 26 THE UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 27 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)



List of Figures


FIGURES LIST
FIGURE 1 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 2 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY TYPES 2018 & 2027 (%)
FIGURE 3 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GENERIC APIS 2019-2027 ($ MILLION)
FIGURE 4 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY INNOVATIVE APIS 2019-2027 ($ MILLION)
FIGURE 5 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY MANUFACTURERS 2018 & 2027 (%)
FIGURE 6 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CAPTIVE APIS 2019-2027 ($ MILLION)
FIGURE 7 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MERCHANT APIS 2019-2027 ($ MILLION)
FIGURE 8 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY SYNTHESIS 2017 & 2027 (%)
FIGURE 9 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BIOTECH 2019-2027 ($ MILLION)
FIGURE 10 NORTH AMERICA BIOTECH MARKET BY MONOCLONAL ANTIBODIES 2019-2027 ($ MILLION)
FIGURE 11 NORTH AMERICA BIOTECH MARKET BY RECOMBINANT PROTEINS 2019-2027 ($ MILLION)
FIGURE 12 NORTH AMERICA BIOTECH MARKET BY VACCINES 2019-2027 ($ MILLION)
FIGURE 13 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHETIC 2019-2027 ($ MILLION)
FIGURE 14 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY APPLICATION 2018 & 2027 (%)
FIGURE 15 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CARDIOVASCULAR DISEASE 2019-2027 ($ MILLION)
FIGURE 16 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ONCOLOGY 2019-2027 ($ MILLION)
FIGURE 17 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CNS AND NEUROLOGICAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 18 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ORTHOPEDIC DISORDERS 2019-2027 ($ MILLION)
FIGURE 19 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ENDOCRINOLOGY 2019-2027 ($ MILLION)
FIGURE 20 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY PULMONOLOGY 2019-2027 ($ MILLION)
FIGURE 21 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GASTROINTESTINAL DISORDERS 2019-2027 ($ MILLION)
FIGURE 22 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY NEPHROLOGY 2019-2027 ($ MILLION)
FIGURE 23 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OPHTHALMOLOGY 2019-2027 ($ MILLION)
FIGURE 24 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OTHER APPLICATION 2019-2027 ($ MILLION)
FIGURE 25 PORTER’S FIVE FORCE MODEL
FIGURE 26 THE UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
FIGURE 27 CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

 

List of Tables


TABLES LIST
TABLE 1 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)
TABLE 2 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 3 NORTH AMERICA GENERIC APIS MARKET 2019-2027 ($ MILLION)
TABLE 4 NORTH AMERICA INNOVATIVE APIS MARKET 2019-2027 ($ MILLION)
TABLE 5 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURERS 2019-2027 ($ MILLION)
TABLE 6 NORTH AMERICA CAPTIVE APIS MARKET 2019-2027 ($ MILLION)
TABLE 7 NORTH AMERICA MERCHANT APIS MARKET 2019-2027 ($ MILLION)
TABLE 8 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHESIS 2019-2027 ($ MILLION)
TABLE 9 NORTH AMERICA BIOTECH MARKET 2019-2027 ($ MILLION)
TABLE 10 NORTH AMERICA BIOTECH MARKET BY TYPES 2019-2027 ($ MILLION)
TABLE 11 NORTH AMERICA MONOCLONAL ANTIBODIES MARKET 2019-2027 ($ MILLION)
TABLE 12 NORTH AMERICA RECOMBINANT PROTEINS MARKET 2019-2027 ($ MILLION)
TABLE 13 NORTH AMERICA VACCINES MARKET 2019-2027 ($ MILLION)
TABLE 14 NORTH AMERICA SYNTHETIC MARKET 2019-2027 ($ MILLION)
TABLE 15 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 16 NORTH AMERICA CARDIOVASCULAR DISEASE MARKET 2019-2027 ($ MILLION)
TABLE 17 NORTH AMERICA ONCOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 18 NORTH AMERICA CNS AND NEUROLOGICAL DISORDERS MARKET 2019-2027 ($ MILLION)
TABLE 19 NORTH AMERICA ORTHOPEDIC DISORDERS MARKET 2019-2027 ($ MILLION)
TABLE 20 NORTH AMERICA ENDOCRINOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 21 NORTH AMERICA PULMONOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 22 NORTH AMERICA GASTROINTESTINAL DISORDERS MARKET 2019-2027 ($ MILLION)
TABLE 23 NORTH AMERICA NEPHROLOGY MARKET 2019-2027 ($ MILLION)
TABLE 24 NORTH AMERICA OPHTHALMOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 25 NORTH AMERICA OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
TABLE 26 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 27 ACTIVE PHARMACEUTICAL INGREDIENTS COMPANY MARKET POSITION ANALYSIS 2017